PL3480213T3 - Polipeptydy syntac i ich zastosowania - Google Patents

Polipeptydy syntac i ich zastosowania

Info

Publication number
PL3480213T3
PL3480213T3 PL18212801T PL18212801T PL3480213T3 PL 3480213 T3 PL3480213 T3 PL 3480213T3 PL 18212801 T PL18212801 T PL 18212801T PL 18212801 T PL18212801 T PL 18212801T PL 3480213 T3 PL3480213 T3 PL 3480213T3
Authority
PL
Poland
Prior art keywords
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
PL18212801T
Other languages
English (en)
Polish (pl)
Inventor
Ronald D. SEIDEL III
Rodolfo J. Chaparro
Brandan S. Hillerich
Scott J. Garforth
Steven C. Almo
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of PL3480213T3 publication Critical patent/PL3480213T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18212801T 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania PL3480213T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
EP15809277.5A EP3157552B1 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
EP18212801.7A EP3480213B1 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PL3480213T3 true PL3480213T3 (pl) 2020-05-18

Family

ID=54936224

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18212801T PL3480213T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania
PL15809277T PL3157552T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15809277T PL3157552T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Country Status (15)

Country Link
US (5) US20170058015A1 (enExample)
EP (3) EP3480213B1 (enExample)
JP (4) JP6652932B2 (enExample)
KR (1) KR102252119B1 (enExample)
CN (3) CN113248624B (enExample)
AU (3) AU2015277460B2 (enExample)
DK (2) DK3480213T3 (enExample)
ES (2) ES2770330T3 (enExample)
HU (2) HUE048076T2 (enExample)
IL (3) IL248979B (enExample)
PL (2) PL3480213T3 (enExample)
PT (2) PT3157552T (enExample)
SG (2) SG11201609876TA (enExample)
TW (3) TWI696633B (enExample)
WO (1) WO2015195531A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
AU2017226269B2 (en) * 2016-03-02 2021-10-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20190046648A1 (en) * 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
JP7071288B2 (ja) * 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
IL309479A (en) * 2017-03-15 2024-02-01 Cue Biopharma Inc Methods for modulating an immune response
WO2018187190A1 (en) * 2017-04-06 2018-10-11 Albert Einstein College Of Medicine, Inc. Precision activation of hiv-specific ctls to eliminate reactived latent t cells
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
KR20240015159A (ko) * 2017-08-10 2024-02-02 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
IL272085B2 (en) * 2017-09-07 2023-03-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019051094A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTATION POLYPEPTIDES AND METHODS OF USE
WO2019051126A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
US11919938B2 (en) * 2017-11-30 2024-03-05 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
RS66546B1 (sr) 2018-03-24 2025-03-31 Regeneron Pharma Genetički modifikovani miševi ili pacovi za dobijanje terapeutskih antitela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
CA3123102A1 (en) * 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
BR112021011838A2 (pt) * 2018-12-19 2021-08-31 Cue Biopharma, Inc. Peptídeos multiméricos moduladores de células t e métodos de uso destes
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
JP2022522405A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
JP7762068B2 (ja) * 2019-05-29 2025-10-29 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20220066075A (ko) * 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3146917A1 (en) * 2019-10-23 2021-04-29 Anish SURI T-cell modulatory chimeric molecules and methods of use thereof
WO2021081232A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
WO2021168122A1 (en) * 2020-02-18 2021-08-26 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
US20230212259A1 (en) * 2020-02-21 2023-07-06 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associate methods of use
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
WO2022197970A2 (en) * 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
EP4334453A4 (en) * 2021-05-07 2025-09-03 Inst Systems Biology SINGLE-CHAIN TRIMER MHC CLASS I NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE THEREOF
KR20240046251A (ko) 2021-08-16 2024-04-08 리제너론 파아마슈티컬스, 인크. 신규 il27 수용체 효능제 및 그의 사용 방법
WO2023023641A2 (en) * 2021-08-20 2023-02-23 3T Biosciences, Inc. Peptide-hla-b*35 libraries, associated compositions, and associated methods of use
EP4460515A1 (en) * 2022-01-03 2024-11-13 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
WO2023205728A2 (en) * 2022-04-21 2023-10-26 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
IL321908A (en) 2023-01-27 2025-09-01 Regeneron Pharma Different rhabdomyovirus glycoproteins and their use
US20240287186A1 (en) 2023-02-28 2024-08-29 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP4608184B2 (ja) * 2001-03-14 2011-01-05 ダコ デンマーク アクティーゼルスカブ 新規なｍｈｃ分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにｍｈｃ分子の使用
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
NZ606427A (en) * 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CA2887486A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Also Published As

Publication number Publication date
EP3480213A1 (en) 2019-05-08
AU2015277460B2 (en) 2020-10-08
JP2020022491A (ja) 2020-02-13
IL248979B (en) 2020-06-30
JP2017519491A (ja) 2017-07-20
EP3483179B1 (en) 2020-09-16
WO2015195531A3 (en) 2016-02-25
PL3157552T3 (pl) 2020-05-18
BR112016027897A2 (pt) 2017-10-24
PT3480213T (pt) 2020-02-04
PT3157552T (pt) 2020-01-22
SG11201609876TA (en) 2017-01-27
IL248979A0 (en) 2017-01-31
IL266570A (en) 2019-07-31
US20180282392A1 (en) 2018-10-04
AU2021204594A1 (en) 2021-07-29
EP3157552A4 (en) 2017-11-22
TW201613966A (en) 2016-04-16
AU2021204594B2 (en) 2024-05-09
TWI696633B (zh) 2020-06-21
AU2015277460A1 (en) 2016-11-24
KR102252119B1 (ko) 2021-05-17
CA2947489A1 (en) 2015-12-23
CN113248624B (zh) 2025-02-07
EP3483179A1 (en) 2019-05-15
ES2770330T3 (es) 2020-07-01
HUE048076T2 (hu) 2020-07-28
IL275307A (en) 2020-07-30
EP3480213B1 (en) 2019-11-13
CN106456733B (zh) 2021-03-16
US20200377569A1 (en) 2020-12-03
DK3157552T3 (da) 2020-01-13
TW202124435A (zh) 2021-07-01
TW201946933A (zh) 2019-12-16
JP7331075B2 (ja) 2023-08-22
JP6652932B2 (ja) 2020-02-26
TWI795740B (zh) 2023-03-11
JP2020072733A (ja) 2020-05-14
AU2019203442A1 (en) 2019-06-06
TWI722576B (zh) 2021-03-21
DK3480213T3 (da) 2020-02-17
US20210238254A1 (en) 2021-08-05
HUE047255T2 (hu) 2020-04-28
US20170058015A1 (en) 2017-03-02
AU2019203442B2 (en) 2021-04-08
EP3157552A2 (en) 2017-04-26
SG10202006338UA (en) 2020-08-28
CN113248623A (zh) 2021-08-13
KR20170030484A (ko) 2017-03-17
US20210047384A1 (en) 2021-02-18
EP3157552B1 (en) 2019-10-23
IL266570B (en) 2020-06-30
JP2022046544A (ja) 2022-03-23
CN106456733A (zh) 2017-02-22
IL275307B (en) 2022-03-01
JP6995151B2 (ja) 2022-02-21
JP6652680B2 (ja) 2020-02-26
WO2015195531A2 (en) 2015-12-23
CN113248624A (zh) 2021-08-13
ES2767259T3 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
SG10201912019WA (en) Novel specific-binding polypeptides and uses thereof
IL250502B (en) New polypeptides
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
GB201410031D0 (en) Polypeptides and uses thereof
IL254241A0 (en) Etv2 and its uses
IL251289B (en) New peptide derivatives and their use
SG11201610918RA (en) Peptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof
GB201401973D0 (en) Antibody polypeptides and uses thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201403024D0 (en) Polypeptides
GB201407419D0 (en) Conductive materials and uses thereof
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning